N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Moscow, Russia.
A. I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of the Russian Federation, Moscow, Russia.
Bull Exp Biol Med. 2020 Mar;168(5):673-676. doi: 10.1007/s10517-020-04778-w. Epub 2020 Apr 4.
The study compared the levels of MMP-2,7,8,9, and TIMP-1 in blood serum of healthy people (N=97) and patients with primary renal cell carcinoma (N=93) to assess relevance of these markers to prognosis of overall survival of these patients, which were followed-up over 1 to 45 months (median 26 months). To evaluate the survival with the Kaplan-Meier estimator, the median values of examined markers in the total group of patients were taken as the threshold levels. This estimator showed that the high levels of serum MMP-7 and MMP-8 were indicative for unfavorable prognosis in the total group of patients with renal cell cancer. Of them, the most significant marker was the level of MMP-7: at its low level (<6.3 ng/ml), a 3-year survival was 93%, whereas survival dropped down to 51% at a higher value of this marker (p<0.001). For MMP-8, the threshold level was 51 ng/ml, and the corresponding survivals were 78 and 58% (p<0.01). The level of MMP-7 was also prognostically significant for the patients with stage I kidney cancer: during a 3-year follow-up, all the patients with low MMP-7 were alive, while the 3-year survival of the patients with a high level of MMP-7 was only 72% (p=0.02). There were the declining trends for survival at high TIMP-1 and low MMP-2. In contrast, the level of MMP-9 virtually did not correlate with survival of the patients with renal cell cancer.
本研究比较了健康人（N=97）和原发性肾细胞癌患者（N=93）血清中 MMP-2、7、8、9 和 TIMP-1 的水平，以评估这些标志物与这些患者总生存预后的相关性，这些患者的随访时间为 1 至 45 个月（中位数 26 个月）。为了用 Kaplan-Meier 估计器评估生存情况，将总患者组中检查标志物的中位数作为阈值水平。该估计器表明，血清 MMP-7 和 MMP-8 水平较高提示肾细胞癌总患者群体预后不良。其中，MMP-7 是最显著的标志物：其水平较低（<6.3ng/ml）时，3 年生存率为 93%，而该标志物水平较高时，生存率降至 51%（p<0.001）。对于 MMP-8，阈值水平为 51ng/ml，相应的生存率为 78%和 58%（p<0.01）。MMP-7 水平对 I 期肾癌患者也具有预后意义：在 3 年随访期间，所有 MMP-7 水平较低的患者均存活，而 MMP-7 水平较高的患者 3 年生存率仅为 72%（p=0.02）。TIMP-1 水平较高和 MMP-2 水平较低与生存率呈下降趋势。相比之下，MMP-9 水平与肾细胞癌患者的生存几乎没有相关性。
